REG - Clean Power Hydrogen - Operations & Trading Update

Clean Power HydrogenAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd5517Ya&default-theme=true

RNS Number : 5517Y  Clean Power Hydrogen PLC  30 March 2026

 

Clean Power Hydrogen plc

("CPH2" or the "Company")

 

Operations & Trading Update

 

CPH2 (AIM:CPH2), the developer of the market disrupting and IP-protected
Membrane-Free Electrolyser ("MFE") technology for the production of high
purity hydrogen and above medical-grade purity oxygen, announces an
operations and trading update.

 

Commercial Progress

The first of the Company's 1MW MFE220 units has left the factory to complete
the third and final stage of its Factory Acceptance Test ("FAT") at the
Company's dedicated test-site. CPH2 has firm orders for four units and a
strong and credible sales pipeline is being built, with a significant increase
in new customer opportunities in UK, India and the Middle East, including a
number of which are now backed by Memoranda of Understanding and / or Letters
of Intent.

 

On 24 March 2026, the Company announced that it had signed a non-binding
agreement with Siemens to explore opportunities to upscale production and
accelerate technology advances. When formalised, the Siemens agreement will
support CPH2 with product, process and technology development, customer
introductions and go-to-market strategies.

 

In addition, CPH2 has entered into non-binding collaboration arrangements
with:

·      Zero Carbon Consultants to develop the supply, install,
commissioning and maintenance of up to 20MW of membrane-free electrolysis
capacity for its wind farm project 'Community Energy Projects';

 

·      Amman Renewable Energy Company (AREC) which is representing CPH2
in Jordan, Syria, Iraq and Saudi Arabia for potential projects of up to 20MW
capacity; and

 

·      Allround Agritech Solutions Private Limited, India, which is
developing agricultural production solutions potentially requiring up to 20MW
of CPH2 membrane-free electrolysers.

 

The growing sales pipeline also includes additional and credible negotiations
underway from customers in Germany, Austria and Ireland, building on existing
orders in the island of Ireland and New Zealand.

 

Operations Update

Level two of the MFE220 FAT for the first of the Company's 1MW MFE220 units
has been achieved and signed off by Lagan MEICA Limited ("Lagan"), the
principal contractor to Northern Ireland Water ("NIW"), and ARUP, representing
NIW.

 

The Company is on track to complete the third and final stage of the FAT in
April 2026, which will be witnessed and signed off by ARUP and Lagan at that
time. This will be a landmark milestone, demonstrating the successful
operation and customer acceptance of the first 1MW commercial electrolyser in
this new category and de-risking the subsequent repeated test (Site Acceptance
Test) at the customer's site in Q3 2026, triggering first commercial revenues
for CPH2.

 

Technology Advances

The Company's scaled demonstrator unit, the MFE110, has demonstrated
independently verified higher-value hydrogen purity of 99.999vol%, exceeding
fuel cell grade purity requirements, and oxygen of 99.7%, exceeding medical
grade purity requirements and marking a clear contrast with traditional
electrolysers which are required to vent their lower purity oxygen.

 

This performance, combined with delivering a high value oxygen co-product,
opens new market opportunities and technology applications for CPH2 and new
revenue streams for operators, further lowering the lifetime levelised cost of
hydrogen ("LCOH") based on the EU Commissions' published methodology. Part of
the Company's technology roadmap is to demonstrate higher levels of oxygen
purity, into the 'ultra-high-purity' (UHP) grade of oxygen, which could
significantly improve project economics in certain use cases.

 

Looking forward, the Company expects the second generation of its 1MW unit,
the MFE220 Mark II, to complete FEED (Front-End Engineering Design) by
December 2026, with final design in 2027 and first build in 2028.

 

Separately the Company is targeting to finalise the concept design for its
first 5MW MFE unit in December 2026, with FEED to complete in 2027 and final
design in 2028, with market leading efficiency of 48kWh/kg/H2 targeted.

 

Jon Duffy, CEO of CPH2, commented: "We have proven and patented technology for
the production of high purity hydrogen and medical-grade oxygen, tailored for
the growing part of the market. In an unstable world, alternative energy
sources are vital. Where electrification is unsuitable, CPH2 technology can
support decentralised energy projects everywhere. With new technology
partners, a growing sales pipeline and activating licensees, we are
accelerating our commercialisation phase while our future product roadmap
holds out the realistic prospect of negative cost hydrogen for the right
application."

 

ENDS

 

Enquiries:

 

Clean Power Hydrogen
plc
            +44 130 232 8705

Jon Duffy, Chief Executive Officer

James Hobson, Chief Financial Officer

 

Cavendish Capital Markets Limited - NOMAD & Joint Broker

Neil
McDonald
+44 131 220 9771

Peter
Lynch
+44 131 220 9772

 

Turner Pope Investments (TPI) Limited - Joint Broker

Andy Thacker

Guy
McDougall
                        +44 203 657 0050

 

Background on CPH2

CPH2 is the holding company of Clean Power Hydrogen Group Limited which has a
decade of dedicated research and product development experience that has
delivered global patents in breakthrough hydrogen and oxygen production
technology. The Group's strategic objective is to deliver the lowest lifetime
Levelised Cost of Hydrogen ("LCoH") in the market in relation to the
production of hydrogen for the growing decentralised markets, which include
wastewater treatment, curtailed wind power capture, data centre backup,
medical and life sciences, and heavy-duty mobility applications. CPH2 is
listed on the AIM market and trades under the ticker AIM:CPH2.

 

For more information: https://www.cph2.com (https://www.cph2.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTMZGZFRLFGVZM



            Copyright 2019 Regulatory News Service, all rights reserved